Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

Drug Profile

Research programme: proto oncogene proteins c-akt inhibitors - Astex/Institute of Cancer Research/Cancer Research Technology

Alternative Names: AT 11854; AT 7867; CCT 128930; CCT 129254; CCT077373; CCT077933

Latest Information Update: 16 Oct 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astex Therapeutics; Cancer Research UK; The Institute of Cancer Research
  • Developer Astex Pharmaceuticals; Cancer Research UK; The Institute of Cancer Research
  • Class Benzamides; Piperidines; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action 70 kDa ribosomal protein S6 kinase inhibitors; Proto oncogene protein c-akt inhibitors; Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Oct 2013 Astex Pharmaceuticals has been acquired by Otsuka Pharmaceutical
  • 20 Jul 2011 Astex Therapeutics has been acquired by SuperGen
  • 21 Apr 2010 Preclinical pharmacodynamics data presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top